Search bioRxiv⌕ Search

Biology subjects

Trucu, D.

Publications and source records attributed to Trucu, D..

3 recordsLinked to original sources

A Computational Pipeline for Physiologically Informed Calibration of Ligand Reaction-Diffusion Models Using High-Throughput Sequencing

All physiological processes fundamentally rely on continuous cellular cross-talk to maintain organization and ensure proper function. Among the various modes of cellular communication, ligand-mediated chemical signaling, in which a ligand is secreted by one cell, diffuses through the extracellular environment, and binds to a receptor on another (or the same) cell to elicit a downstream response, is arguably the most ubiquitous and foundational. Given its importance, numerous mathematical models have been developed to describe this reaction-diffusion mechanism, capturing ligand secretion, diffusion, decay, and binding under both normal and pathological conditions. However, parameter calibration for such models often lags behind model development. This is due to limited data that faithfully represent the biological microenvironment, as well as due to the absence of a robust, rigorous framework to integrate available data into the mathematical model. To address this gap, we propose that transcriptomics (gene expression) data, namely the combination of single-cell RNA sequencing and spatial transcriptomics, provide a rich, increasingly abundant, and underutilized source of information that can be used to calibrate the parameters of the cellular reaction-diffusion models at the larger mesoscopic scale. To this end, we develop a computational pipeline that leverages these data to extract parameter values for reaction-diffusion models, and illustrate its application through two human wound-healing case studies. Using open-source transcriptomics data, we calibrate the reaction-diffusion model parameters of the isoforms of Transforming Growth Factor Beta (TGF{beta}), a signaling molecule central to tissue repair and development as well as to pathological processes such as cancer and fibrosis. Our pipeline integrates traditional numerical (finite volume) solvers for the ligand concentration fields with bioinformatics, machine learning, and Bayesian inference methods, combining existing and novel computational tools into a single framework for a physiologically informed, data-driven parameter calibration process. The pipeline is modular, allowing easy extension or adjustment depending on user needs. Overall, this framework facilitates rigorous model calibration, an essential step toward ensuring that mathematical models have meaningful research and potential translational utility.

systems biology↗

Computational Model of Heterogeneity in Melanoma: Designing Therapies and Predicting Outcomes

Cutaneous melanoma is a highly invasive tumor and, despite the development of recent therapies, most patients with advanced metastatic melanoma have a poor clinical outcome. The most frequent mutations in melanoma affect the BRAF oncogene, a protein kinase of the MAPK signaling pathway. Therapies targeting both BRAF and MEK are effective for only 50% of patients and, almost systematically, generate drug resistance. Genetic and non-genetic mechanisms associated with the strong heterogeneity and plasticity of melanoma cells have been suggested to favor drug resistance but are still poorly understood. Recently, we have introduced a novel mathematical formalism allowing the representation of the relation between tumor heterogeneity and drug resistance and proposed several models for the development of resistance of melanoma treated with BRAF/MEK inhibitors. In this paper, we further investigate this relationship by using a new computational model that copes with multiple cell states identified by single cell mRNA sequencing data in melanoma treated with BRAF/MEK inhibitors. We use this model to predict the outcome of different therapeutic strategies. The reference therapy, referred to as "continuous" consists in applying one drug (or several drugs) without disruption. In "combination therapy", several drugs are used sequentially. In "adaptive therapy" drug application is interrupted when the tumor size is below a lower threshold and resumed when the size goes over an upper threshold. We show that, counter-intuitively, the optimal protocol in combination therapy of BRAF/MEK inhibitors with a hypothetical drug targeting cell states that develop later during the tumor response to kinase inhibitors, is to treat first with this hypothetical drug. Also, even though there is little difference in the timing of emergence of the resistance between continuous and adaptive therapies, the spatial distribution of the different melanoma subpopulations is more zonated in the case of adaptive therapy.

systems biology↗

Spatio-Genetic and Phenotypic Modelling Elucidates Resistance and Re-Sensitisation to Treatment in Heterogeneous Melanoma

Although novel targeted therapies have significantly improved the overall survival of patients with advanced melanoma, understanding and combatting drug resistance remains a major clinical challenge. Using partial differential equations, we describe the evolution of a cellular population through time, space, and phenotype dimensions, in the presence of various drug species. We then use this framework to explore models in which resistance is attained by either mutations (irreversible) or plasticity (reversible). Numerical results suggest that punctuated evolutionary assumptions are more consistent with results obtained from murine melanoma models than gradual evolution. Furthermore, in the context of an evolving tumour cell population, sequencing the treatment, for instance applying immunotherapy before BRAF inhibitors, can increase treatment effectiveness. However, drug strategies which showed success within a spatially homogeneous tumour environment were unsuccessful under heterogeneous conditions, suggesting that spatio-environmental heterogeneity may be the greatest challenge to tumour therapies. Plastic metabolic models are additionally capable of reproducing the characteristic resistant tumour volume curves and predicting re-sensitisation to secondary waves of treatment observed in patient derived xenograft (PDX) melanomas treated with MEK and BRAF inhibitors. Nevertheless, secondary relapse due to a pre-adapted subpopulation, remaining after the first wave of treatment, results in a more rapid development of resistance. Our model provides a framework through which tumour resistance can be understood and would suggest that carefully phased treatments may be able to overcome the development of long-term resistance in melanoma.

cancer biology↗